Key Takeaways:
A securities fraud class action was filed against GRAIL Inc. after its stock lost 50.5%, or $51.32 a share, on Feb. 20.
The complaint, filed in the U.S. District Court for the Northern District of California, alleges the company misled investors about its NHS-Galleri cancer trial, according to Bleichmar Fonti & Auld LLP, which announced the lawsuit. The case is captioned Robbins v. GRAIL, Inc., et al., No. 26-cv-05428.
GRAIL on Feb. 19 disclosed that the "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri trial, attributing the miss in part to "probably need[ing] a longer follow-up time." The stock closed at $50.21 on Feb. 20, down from $101.53 the prior session. The class period covers purchases between May 13, 2025 and Feb. 19, 2026.
The lawsuit claims GRAIL made positive statements about the trial's design and first-round results while concealing that the three-year timeframe was insufficient to demonstrate the primary endpoint. The company had described the trial as "designed with three consecutive years of screening in order to achieve the primary endpoint" and said "Galleri is working in the real world." Investors have until Aug. 4 to seek lead plaintiff status.
The 50% decline puts GRAIL shares at their lowest since the stock's recent trading range, testing support levels not seen since before the trial results. The company's next catalyst will be any court rulings on class certification and the progress of the NHS-Galleri trial under an extended timeline.
This article is for informational purposes only and does not constitute investment advice.
